Together, these results provide the first experimental evidence supporting the potential involvement of STE20-type kinase MAP4K4 as a component of the hepatocellular lipotoxic milieu promoting NAFLD susceptibility. Here, MAP4K4 is linked to metabolic dysfunction-associated steatotic liver disease.